In the current study, the incidence of grade 3–4 thrombocytopenia in the lobaplatin-based chemotherapy group was significantly higher than that observed in the non-lobaplatin-based chemotherapy group (34.4% vs. 1.7%, P < 0.05), and interleukin-11 treatment enabled a return to normal after thrombocytopenia in all but one patient, who stopped the treatment due to the toxicity. This evidence concerns the gene IL11 and Thrombocytopenia.